NDC (National Drug Code)

An NDC (National Drug Code) is the FDA-assigned 10-digit identifier (typically expressed as 11 digits in pharmacy billing using a 5-4-2 segment format with leading zeros) that uniquely identifies a drug product by labeler, product, and package configuration. NDCs are central to pharmacy claim adjudication, PBM audit verification, Medicare and Medicaid billing accuracy, and FDA enforcement against unapproved drugs. NDC errors in claim submission frequently support PBM audit recoupment and FCA exposure when federal payors are involved.

How the NDC framework works

FDA assigns the labeler segment (the first 4 or 5 digits) to each registered manufacturer or distributor. The labeler then assigns the product segment (the next 3 or 4 digits) to each formulation, strength, dosage form, and other distinguishing characteristic. The package segment (the last 1 or 2 digits) identifies the specific package configuration. Pharmacies submit the NDC of the dispensed product as part of every claim. PBMs and government payors verify the NDC against the dispensed product, the prescribed product, and the reimbursement framework.

NDC accuracy audits commonly identify three categories of issue: NDC substitution (a different NDC dispensed than billed), unapproved-drug NDCs (the NDC corresponds to a drug FDA has not approved or has withdrawn approval for), and discontinued NDCs (the NDC is no longer commercially available and the claim was submitted in error or for fraudulent purposes). Each finding category supports recoupment and, in some cases, fraud referral.

When NDC accuracy applies

NDC accuracy applies to every pharmacy claim submission. PBM audits routinely include NDC verification on the sampled claims. Medicare and Medicaid contractor audits do the same. Special enforcement focus has surfaced in unapproved-drug billing matters (where a pharmacy bills with an NDC that does not correspond to an FDA-approved drug), in repackaged-drug billing matters (where a repackager NDC obscures the original manufacturer NDC), and in compounding contexts where the dispensed compounded preparation has no real NDC but the claim submission selects a substitute NDC.

The pharmacy's exposure under NDC findings

NDC findings typically support recoupment of the full claim reimbursement (because the underlying claim is treated as not properly billed). Compounding context findings can additionally support FDA enforcement under the unapproved-drug or misbranding framework. FCA exposure attaches where the NDC errors involve federal payors and the underlying conduct supports knowledge or reckless disregard. The defense framework focuses on the NDC-mapping record, the substitution justification (where applicable), and the methodology challenge where the audit applies statistical extrapolation across the NDC-related claim universe.

Related terms

• PBM audit The audit framework that routinely verifies NDC accuracy on sampled claims.
• DAW The NCPDP code that operates alongside the NDC in claim adjudication for brand-versus-generic substitution.
• Signature log The parallel pharmacy documentation category whose findings often appear alongside NDC findings.
• Recoupment The dollar demand that follows when NDC findings become final.

See also

• Practice area
  PBM Audit Defense

  The PBM audit defense framework covering NDC accuracy findings.

• Practice area
  Recoupment Defense

  Defense framework for NDC-driven recoupment demands.